Semorinemab

• CAT Number: I042198
• CAS Number: 2159141-27-0
• Purity: ≥95%

Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer’s Disease[1].
Semorinemab binds to human Tau and recombinant cynomolgus monkey Tau with Kd values of 3.8 and 11.2 nM, respectively[1].
Semorinemab prevents neurons to uptake oligomeric Tau[1].
Semorinemab (3, 10 and 30 mg/kg; i.p., once weekly for 13 weeks) reduces accumulation of Tau pathology in a transgenic (Tg) mouse model of tauopathy[1].

Reference

[1]. Ayalon G, et al. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease. Sci Transl Med. 2021 May 12;13(593):eabb2639.
 [Content Brief]